CAR2219 CAR-T
/ Hebei Taihe Chunyu Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 07, 2025
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
(clinicaltrials.gov)
- P1/2 | N=90 | Recruiting | Sponsor: Tianjin Medical University General Hospital
New P1/2 trial • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia
February 19, 2025
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
(clinicaltrials.gov)
- P1/2 | N=20 | Recruiting | Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
New P1/2 trial • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD22
1 to 2
Of
2
Go to page
1